One- and Two-Year Outcomes of Switching to a Dolutegravir-Based ART Regimen: An Observational Emulation of Sequential Target Trials
Open Access
- 28 April 2026
- journal article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (5)
Abstract
Background: Clinical trials evaluating the impact of switching to dolutegravir have excluded individuals with poorly controlled viremia. However, in practice, clinicians may switch individuals to dolutegravir who have such challenges. Utilizing the Target Trial Framework, we estimated the effect of switching to a dolutegravir-based regimen, vs not switching and remaining on an efavirenz-based regimen, on 12- and 24-month retention and viral suppression in Johannesburg, South Africa, from 2019 to 2022. Methods: Using data from the Themba Lethu HIV Clinical Cohort, individuals were eligible if they were currently on an efavirenz-based regimen, aged 16+, and not pregnant at the start of each trial. We conducted a pooled linear regression model with bootstrapping to estimate the causal risk difference and 95% CI adjusting for patient characteristics via inverse probability treatment weighting. Results: Of 1493 individuals, 967 (64.7%) switched to a dolutegravir-based regimen over 9 sequential trials, and 526 (35.2%) did not. At 12 months, switch to a dolutegravir-based regimen was associated with a 14 percentage point (95% CI, 0.10 to 0.19) increase in retention and a 2 percentage point (95% CI, −0.04 to 0.08) increase in viral suppression. By 24 months, we observed a 1 percentage point (95% CI, −0.05 to 0.07) increase in retention and an 8 percentage point (95% CI, 0.02 to 0.14) increase in viral suppression. Conclusions: Switching to dolutegravir was associated with a 14 percentage point increase in retention at 12 months and an 8 percentage point increase in viral suppression at 24 months. Our findings suggest that switching to dolutegravir does not harm and might improve retention and viral suppression over a 24-month period.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (K01DK116929 to A.T.B.)
- National Institute of Allergy and Infectious Diseases (F31AI179292 to A.Z.)
- National Institutes of Health
This publication has 28 references indexed in Scilit:
- Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in CameroonThe Lancet HIV, 2020
- Emulating a target trial of statin use and risk of dementia using cohort dataNeurology, 2020
- Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO StudyClinical Infectious Diseases, 2020
- Dolutegravir based antiretroviral therapy compared to other combined antiretroviral regimens for the treatment of HIV-infected naive patients: A systematic review and meta-analysisPLOS ONE, 2019
- Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analysesJournal of Clinical Epidemiology, 2016
- Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trialsAIDS Research and Therapy, 2016
- Cohort Profile: The Themba Lethu Clinical Cohort, Johannesburg, South AfricaInternational Journal of Epidemiology, 2012
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- Matching Methods for Causal Inference: A Review and a Look ForwardStatistical Science, 2010
- Marginal Structural Models and Causal Inference in EpidemiologyEpidemiology, 2000